Lexicon Pharmaceuticals to Participate in December Investor Conferences
Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in two major investor conferences this December. CEO Mike Exton will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 8:00 am ET, and the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024, at 12:30 pm ET.
Live webcasts of both presentations will be accessible through the Events section of Lexicon's website, with recordings available for two weeks after the original broadcasts.
Lexicon Pharmaceuticals (Nasdaq: LXRX) ha annunciato la sua partecipazione a due importanti conferenze per investitori questo dicembre. Il CEO Mike Exton presenterà alla 36ª Conferenza Annuale sulla Salute di Piper Sandler martedì 3 dicembre 2024, alle 8:00 ET, e alla 7ª Conferenza Annuale Evercore HealthCONx giovedì 5 dicembre 2024, alle 12:30 ET.
Le dirette streaming di entrambe le presentazioni saranno disponibili nella sezione Eventi del sito web di Lexicon, con registrazioni disponibili per due settimane dopo le trasmissioni originali.
Lexicon Pharmaceuticals (Nasdaq: LXRX) ha anunciado su participación en dos importantes conferencias para inversores este diciembre. El CEO Mike Exton presentará en la 36ª Conferencia Anual de Atención Médica de Piper Sandler el martes 3 de diciembre de 2024, a las 8:00 am ET, y en la 7ª Conferencia Anual de Evercore HealthCONx el jueves 5 de diciembre de 2024, a las 12:30 pm ET.
Las transmisiones en vivo de ambas presentaciones estarán disponibles a través de la sección de Eventos en el sitio web de Lexicon, con grabaciones accesibles durante dos semanas después de las transmisiones originales.
Lexicon Pharmaceuticals (Nasdaq: LXRX)는 올해 12월 두 개의 주요 투자자 회의에 참가할 것을 발표했습니다. CEO Mike Exton은 2024년 12월 3일 화요일 동부 시간 오전 8시에 Piper Sandler 제36회 연례 헬스케어 회의에서 발표할 예정이며, 2024년 12월 5일 목요일 동부 시간 오후 12시 30분에 Evercore HealthCONx 제7회 연례 회의에서 발표할 예정입니다.
두 발표의 생중계는 Lexicon 웹사이트의 이벤트 섹션을 통해 접근할 수 있으며, 원본 방송 이후 2주 동안 녹화 자료를 제공할 예정입니다.
Lexicon Pharmaceuticals (Nasdaq: LXRX) a annoncé sa participation à deux importantes conférences d'investisseurs en décembre. Le PDG Mike Exton présentera à la 36e Conférence Annuelle sur la Santé de Piper Sandler le mardi 3 décembre 2024 à 8h00 ET, et à la 7e Conférence Annuelle Evercore HealthCONx le jeudi 5 décembre 2024 à 12h30 ET.
Des webdiffusions en direct des deux présentations seront accessibles via la section Événements du site Web de Lexicon, avec des enregistrements disponibles pendant deux semaines après les diffusions originales.
Lexicon Pharmaceuticals (Nasdaq: LXRX) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember angekündigt. CEO Mike Exton wird am Dienstag, den 3. Dezember 2024, um 8:00 Uhr ET auf der 36. jährlichen Healthcare-Konferenz von Piper Sandler präsentieren und am Donnerstag, den 5. Dezember 2024, um 12:30 Uhr ET auf der 7. jährlichen Evercore HealthCONx-Konferenz.
Live-Streaming beider Präsentationen wird über den Bereich Veranstaltungen auf der Lexicon-Website zugänglich sein, mit Aufzeichnungen, die zwei Wochen nach den ursprünglichen Übertragungen verfügbar sein werden.
- None.
- None.
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer and director, will present at two upcoming investor conferences in December.
- Piper Sandler 36th Annual Healthcare Conference: Presentation Tuesday, December 3, 2024 at 8:00 am ET
- 7th Annual Evercore HealthCONx Conference: Presentation Thursday, December 5, 2024 at 12:30 pm ET
Simultaneous webcasts will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events, and a recording of the webcasts will be available for two weeks following the original on-demand date.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.
Investors and Media
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
When is Lexicon Pharmaceuticals (LXRX) presenting at the Piper Sandler Healthcare Conference in December 2024?
What time is Lexicon Pharmaceuticals (LXRX) presenting at the Evercore HealthCONx Conference in December 2024?
How long will the webcasts of Lexicon Pharmaceuticals' (LXRX) December 2024 investor conferences be available?
Where can I watch Lexicon Pharmaceuticals' (LXRX) December 2024 investor conference presentations?
